x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Beyond Biotech - the podcast from Labiotech

Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what"s happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.

news tech news

All Episodes

49:07

Are next-generation psychedelics the way forward for...

Beyond Biotech - the podcast from Labiotech ·

2025/08/15

Nearly 1 billion people around the world suffer from mental health disorders, with the global economic cost of those disorders expected to reach $6 trillion by 2030. One of the most common of those mental health disorders is depressive disorder, commonly called depression, with some 280 million people suffering from either mild, moderate or severe depression. Conventional treatments for depression such as selective serotonin reuptake inhibitors, or SSRIs, can work for many people but fo...

en-us

49:57

Day One DNA: How and why the UK is betting on whole...

Beyond Biotech - the podcast from Labiotech ·

2025/08/08

The UK is preparing to change the game for healthcare - but why, how, and what will it cost? Recently the UK government announced plans to sequence the DNA of every baby born in that country. A part of the country’s 10 Year Health Plan, the program aims to identify rare genetic diseases early, prevent harms from delayed treatment and reduce future healthcare costs for the NHS. Yet along with those potential upsides come a range of ethical and practical questions, too: who guards the sequenced...

en-us

38:45

Meatly's innovative cultivated meat is already...

Beyond Biotech - the podcast from Labiotech ·

2025/08/01

Is cultivated meat the future of pet food? And is there a place for cultivated meat on human dinner tables, too? Traditional agricultural methods are slow, require large tracts of land, significant energy and environmental inputs, and – somewhat obviously – the slaughter of hundreds of millions of animals every year. Cultivated meat – that is meat that is grown in a lab – requires little land, less energy, and in the case of Meatly, nothing more than a single cell from a single chicken egg, o...

en-us

48:30

Cryoport Systems on the state of the ATMP market and...

Beyond Biotech - the podcast from Labiotech ·

2025/07/25

With supply chain management and optimization, risk management, and the capacity to address global markets efficiently and effectively top of mind for all growing biotechs, I'm excited to be joined by Alison Pritchard, Vice President, Business Development at Cryoport Systems, to learn more about how they support life science innovators worldwide. Cryoport Systems evolved alongside the life science industry and expanded its capabilities into full-scale supply chain management solutions t...

en-us

39:24

Taking the fight to inflammatory disease: InflaRx’s...

Beyond Biotech - the podcast from Labiotech ·

2025/07/18

Inflammatory diseases involve excessive or ongoing inflammation that damages tissues and affects many different human systems, including digestion, immunity, circulation, breathing, and the nervous system. The demand for anti-inflammatory treatments is growing quickly and is tipped to top a quarter of a trillion dollars within the decade as cases increase and new approaches to address inflammation emerge. This week, I had the chance to talk to Niels Riedemann, CEO and Founder of InflaRx, abou...

en-us

34:27

How OMass Therapeutics is tackling congenital adrenal...

Beyond Biotech - the podcast from Labiotech ·

2025/07/11

Ros Deegan is an industry leader and the CEO of OMass Therapeutics, an Oxford-based biotechnology company discovering medicines against highly-validated target ecosystems, such as membrane proteins or intracellular complexes. OMass’s MC2 program targeting Congenital Adrenal Hyperplasia, or CAH, is set to enter the clinic this year and in our interview today she walks me through how the company is preparing for their trials, how their approach differs to existing treatment options, and ...

en-us

38:29

Persica Pharmaceuticals is treating the cause of...

Beyond Biotech - the podcast from Labiotech ·

2025/07/04

The World Health Organization reports that more than 600 million people suffer from lower back pain globally, making it the leading cause of disability worldwide. Chronic lower back pain – where the pain persists for more than 3 months – develops in between 5 and 10% of all lower back pain cases, with life-altering impacts for patients. And that’s where today’s guest, Steve Ruston, of Persica Pharmaceuticals comes in. Persica is developing a groundbreaking and transformative treatment f...

en-us

36:27

Humacyte: Saving lives with lab-grown blood vessels...

Beyond Biotech - the podcast from Labiotech ·

2025/06/27

Trauma surgeons in Ukraine operating theaters saved lives and limbs thanks to the innovative lab-grown blood vessels from US biotech, Humacyte. Humacyte is pioneering a platform that enables the investigation, development, and manufacture of bioengineered human tissues and organs that are designed to be universally implantable, off-the-shelf, and regenerative, with the goal of treating a wide variety of diseases, injuries, and chronic conditions. This week I had the chance to speak to Humacyt...

en-us

38:20

Special Episode: The 2025 BIO International Convention

Beyond Biotech - the podcast from Labiotech ·

2025/06/20

Much of the attention of the biotech industry has been focused on the city of Boston this week as the annual BIO International Convention hit town. BIO is the world’s largest partnering conference for the biopharma industry and thousands of innovators, out-licensors, venture capitalists, top pharma dealmakers, thought leaders and more than a few politicians gathered for three days of meetings, presentations, and networking. In this week’s episode we meet three innovators on the floor in...

en-us

46:26

Alex Telford on AI, drug discovery, digital twins,...

Beyond Biotech - the podcast from Labiotech ·

2025/06/13

What are the most interesting questions in biotech, and is it even possible to find answers to those questions? Alex Telford is the co-founder of Convoke and a biotech blogger from the San Francisco Bay Area. His blog post, 'Some questions about biotech that I find interesting' provoked conversations online as readers engaged with questions about topics as diverse as the impacts of regulation, the role of serendipity in drug discovery, clinical trial failure rates, and the best structure for ...

en-us

42:12

Corporate venture capital and biotechnology in 2025:...

Beyond Biotech - the podcast from Labiotech ·

2025/06/06

When biotechs start fundraising they regularly turn to the venture capital market seeking investment. The pool of VC money can be large, and part of that pool is corporate venture capital. Backed by firms keen to identify the next big thing in biotechnology, corporate VC money can be an attractive way for biotechs to raise funds privately while benefiting from the support and expertise of corporate supporters. This week I talked with Paolo Di Giorgio and Regina Hodits of Angelini Ventures, th...

en-us

39:27

The state of biotech finance and fundraising in Q2...

Beyond Biotech - the podcast from Labiotech ·

2025/05/30

Biotechnology has always been a dynamic domain, but the world of finance that provides the fuel for the fire is just as vibrant. Trying to predict where the market for biotech investment is heading is always risky but for experts like Baker McKenzie’s Roel Meers, understanding where the market is moving is where he eats. I spoke to Roel this week to unpack just where biotech funding stands in Q2 2025, to get a feel for the sorts of M&As, IPOs, and licensing deals we should be looking for ...

en-us

35:00

How generative AI and 'Photoshop for proteins' are...

Beyond Biotech - the podcast from Labiotech ·

2025/05/23

Generative artificial intelligence (GenAI) is already changing how people research, communicate, and interact, but its biggest impacts on biotech are still to come. Cradle is a Dutch-Swiss biotech startup founded in 2021 that has developed a web-based software platform leveraging GenAI to accelerate protein design and optimization, aiding scientists in biotechnology R&D. Cradle’s technology integrates AI with wet lab experimentation, doubling the speed of most projects compared to industr...

en-us

33:52

Fighting mucopolysaccharidosis type I, a rare...

Beyond Biotech - the podcast from Labiotech ·

2025/05/16

There are cell therapies, gene therapies, and biologics – and then there is Immusoft. Immusoft sits at the nexus point of some of the most innovative approaches in biopharma, and their Immune System Programming platform is unique in its capacity to address the rare disease, MPS I. This week we talk with Immusoft CEO Sean Ainsworth to learn more about his journey in biotechnology, the work that Immusoft is doing in B-cell reprogramming and unpack some of the positive results that t...

en-us

44:25

Inside Flagship Pioneering's strategy: How this VC...

Beyond Biotech - the podcast from Labiotech ·

2025/05/09

Flagship Pioneering doesn't go out to find the next big thing in biotech when investing their billions in fund capital - instead, they take a different route. Flagship Pioneering has founded more than 100 companies in the life sciences worth in total an estimated $75 billion. With a proven model for biotech startup success and a culture designed to surface new and interesting ideas, Flagship offers a different approach to biotech funding that is paying off time and again. In this episode I ta...

en-us

34:00

TCR-NK: A novel cell therapy transforming cancer...

Beyond Biotech - the podcast from Labiotech ·

2025/05/02

Are TCR-NK treatments the next big thing in cell therapies for cancer patients? As biotechs and pharma companies continue to innovate to address patient needs in oncology, T-cell receptor therapies, or TCR-Ts, are attracting significant interest and investment. There are already some promising results for TCR-Ts tackling solid tumors – but one Norwegian biotech is taking a slightly different track. This week, we sit down with Namir Hassan, CEO of Zelluna, a company with a mission to eliminate...

en-us

39:40

AI in biotech today, and how it will impact the...

Beyond Biotech - the podcast from Labiotech ·

2025/04/25

AI is driving innovation across industries, including biotech, but where is its influence felt most and what opportunities for future impact are emerging? David del Bourgo is the co-founder and CEO of WhiteLab Genomics, an innovative biotech that is leveraging the power of AI to accelerate drug discovery and development from its Paris, Boston, and Montreal bases. In this episode he explains how WhiteLab uses AI technologies to identify targets and engineer vectors, but also offers a wider vie...

en-us

41:13

How nanobodies will revolutionize immunotherapy

Beyond Biotech - the podcast from Labiotech ·

2025/04/11

From llamas and camels to humans worldwide. Nanobodies are enjoying success in the clinic and experts are hailing these camelid-derived biologics as one of the next big things in immunotherapy. Kristian Reich is co-founder and CSO of MoonLake Immunotherapeutics. After a long and distinguished career as a clinician and researcher, Kristian helped to launch MoonLake in 2021 and quickly helped move their lead candidate to the clinic. Now, on the verge of Phase III trials, he joins 'Beyond Biotec...

en-us

39:38

Meeting the global demand for cell therapies: scaling...

Beyond Biotech - the podcast from Labiotech ·

2025/04/04

Cell therapies are at the cutting edge of personalized medicine but as demand for these therapies grows, how will the industry scale manufacturing to meet patient needs? Fabian Gerlinghaus is co-founder and CEO of Cellares. He and his team have developed the Cell Shuttle, an advanced cell manufacturing technology that is already demonstrating the potential to 10x cell yields while halving costs for pharmaceuticals companies and innovators. Is this the future for smart cell manufacturing? 0:52...

en-us

33:48

Treating spinal cord injuries with stem cells

Beyond Biotech - the podcast from Labiotech ·

2025/03/28

Spinal cord injuries impact millions of people worldwide and, unlike many chronic injuries, they usually arrive with no forewarning, impacting the young and old alike. Brian Culley is CEO of Lineage Cell Therapeutics and his company is now in the clinic with a stem cell therapy for spinal cord injuries. Learn why stem cells could be promising for these devastating injuries and how Brian and his team plan to overcome the challenges of manufacturing at scale and succeeding in a highly regulated...

en-us

180 results

Similar Podcasts

Expres Ráno

Expres FM

PBS News Hour - Full Show

PBS News

CD Voice

China Daily

Israel Today: Ongoing War Report

Noa Levi

Jeffrey Epstein: The Coverup Chronicles

Bobby Capucci